Navigation Links
The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
Date:12/1/2008

CHICAGO, Dec. 1 /PRNewswire-FirstCall/ -- The Female Health Company (Amex: FHC), which manufactures and markets the FC Female Condom(R), today reported record operating results for the quarter and fiscal year ended September 30, 2008.

For the three months ended September 30, 2008, net revenues increased 52% to $7.8 million, compared with $5.2 million in the quarter ended September 30, 2007. The Company reported net income attributable to common stockholders of $2.3 million, or $0.08 per diluted share, in the fourth quarter of FY2008, versus $1.1 million, or $0.04 per diluted share, in the corresponding period of the previous fiscal year.

In the fourth quarter of FY2008, the Company recorded a favorable currency gain of $0.9 million and a tax benefit of $0.2 million. Pretax income exclusive of currency gain totaled $1.3 million, an increase of 211% when compared with pretax income exclusive of currency loss of $0.4 million in the final quarter of FY2007.

Gross profit increased 73% to $3.5 million, or 44.8% of net revenues, in the most recent quarter, compared with $2.0 million, or 39.3% of net revenues, in the fourth quarter of FY2007. Operating income increased 206% to $1.2 million in the three months ended September 30, 2008, compared with $0.4 million in the corresponding period of the previous fiscal year. This was the first quarter in which the Company reported operating income in excess of $1 million.

The Company expects significant quarter-to-quarter variations in its operating results, due to the timing of large order receipts, production scheduling, and shipping of products.

For the year ended September 30, 2008, net revenues increased 33% to $25.6 million, compared with $19.3 million in FY2007. Gross profit increased 50% to $10.7 million, or 41.9% of net revenues, in FY2008, compared with $7.2 million, or 37.0% of net revenues, in FY2007. Operating income rose to $3.2 million, a 252% improvement from $0.9 million in FY2007. In FY2008, the Company sold 34.7 million female condoms, an increase of 34% over the 25.9 million units sold in FY2007.

Net income attributable to common stockholders for FY2008 totaled $4.8 million, or $0.18 per diluted share, representing a 215% increase when compared with net income attributable to common stockholders of $1.5 million, or $0.06 per diluted share, in FY2007. In FY2008, the Company recorded a currency gain of $1 million and recognized a tax benefit of $0.8 million. Pretax income exclusive of the currency gain totaled $3.2 million, which represented an increase of 245% over FY2007 pretax net income exclusive of currency loss of $0.9 million. The Company's pretax earnings guidance for FY2008 was an increase of 200% to 250% over pretax earnings for FY2007

The Company generated $4.2 million in cash from operations during FY2008, and its fiscal year-end cash position was approximated $2.1 million, compared with $0.9 million at the end of FY2007. Cash expenditures in FY2008 included approximately $2.7 million for capital improvements and common stock repurchases and preferred stock redemptions. The Company currently has no outstanding debt and $1.5 million in unused credit lines.

In January 2007, the Company announced a Stock Repurchase Program under the terms of which up to one million shares of its common stock could be purchased during the subsequent twelve months. In 2008, the Board of Directors expanded the program to a maximum of two million shares and continued the program to December 31, 2009. Through September 30, 2008, the Company has purchased 841,000 shares for $2.1 million (an average price of $2.54 per share).

"We are pleased to report record sales, earnings and unit shipments in the most recent fiscal year and believe this strong performance directly reflects the growing demand for the female condom and an expansion in the number of women receiving protection world-wide," stated O.B. Parrish, Chief Executive Officer of The Female Health Company. "The improvement in gross profit margins during fiscal 2008 can be attributed to a shift in product mix towards our second-generation FC2 Female Condom and the spreading of corporate overhead across an expanding revenue base.

"We ended the fiscal year with the strongest balance sheet in our Company's history," continued Parrish. "Total cash balances increased 141% during fiscal 2008 to approximately $2.1 million (vs. approximately $0.9 million), even after our investment of approximately $2.7 million in the repurchase of common stock, redemption of preferred stock and capital improvements during the twelve months ended September 30, 2008.

FY2009 Earnings Guidance: The Company expects unit sales to increase 20% to 25% and pretax earnings exclusive of currency gains or losses to increases 50% to 60% in FY2009.

Investor Conference Call

The Company will host an investor conference call today at 11:00 Eastern Time to discuss FY2008 operating results and other topics of interest.

Shareholders and other interested parties may participate in the conference call by dialing 800-860-2442 (international participants dial 412-858-4600) and asking to be connected to the 'Female Health Company Conference Call', a few minutes before 11:00 a.m. EST on December 1, 2008. A replay of the call will be available one hour after the call through 5:00 pm on December 15, 2008 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID 425576.

Use of Non-GAAP Financial Information

In addition to the results reported in accordance with U.S. generally accepted accounting principles ("GAAP") included in this release, the Company has provided certain non-GAAP financial information, specifically pretax income exclusive of currency (gain) loss. Management believes that the presentation of this non-GAAP financial measure provides useful information to investors because this information may allow investors to better evaluate ongoing business performance and certain components of the Company's results. In addition, because currency gains and losses can fluctuate significantly between periods, the Company believes that the presentation of this non-GAAP financial measures enhances an investor's ability to make period-to-period comparisons of the Company's operating results. This information should be considered in addition to the results presented in accordance with GAAP, and should not be considered a substitute for the GAAP results. The Company has reconciled the non-GAAP financial information included in this release in a table below.

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide rights to FC1. The Company holds exclusive product and technology patents for FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People's Republic of China, South Korea and Japan. Patents are pending for FC2. FHC is the sole manufacturer and marketer of the FC1 and FC2 female condoms in the world.

The Female Health Company and its partners currently market the Female Condom under FC Female Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R), Femy(R), and Care(R) in the rest of the world.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org . If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com .

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include the Company's financial guidance for fiscal 2009. These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings, including the Company's Form 10-KSB for the fiscal year ended September 30, 2007. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

                        (Financial Highlights Follow)



                          The Female Health Company
               Unaudited Condensed Consolidated Balance Sheets

                                               September 30,   September 30,
                                                   2008            2007
    Cash                                        $1,922,148       $799,421
    Restricted cash                                211,873         86,435
    Accounts receivable, net                     6,810,050      6,080,153
    Inventory                                    1,322,652      1,372,582
    Prepaid and other current assets               414,040        399,536
    Deferred income taxes                        1,600,000        825,000
    Total current assets                        12,280,763      9,563,127

    Other non-current assets                        55,330        251,536
    Net property, plant & equipment              1,494,645      1,378,885
    Total assets                               $13,830,738    $11,193,548

    Accounts payable                              $621,115       $806,134
    Accrued expenses                             2,385,540      1,532,170
    Preferred dividends payable                     25,068         53,025
    Total current liabilities                    3,031,723      2,391,329

    Obligations under capital leases                49,597         23,176
    Deferred gain on sale of facilities            836,733      1,074,339
    Deferred grant income                          203,483        257,245
    Total liabilities                            4,121,536      3,746,089

    Total stockholders' equity                   9,709,202      7,447,459
    Total liabilities and stockholders' equity $13,830,738    $11,193,548



                            The Female Health Company
                Unaudited Condensed Consolidated Income Statements

                        For the 3 Months Ended     For the 12 Months Ended
                             September 30,              September 30,
                           2008         2007         2008         2007

    Net revenues        $7,839,973   $5,174,227  $25,634,126  $19,319,889

    Cost of products
     sold                4,326,660    3,143,306   14,904,325   12,163,574

    Gross profit         3,513,313    2,030,921   10,729,801    7,156,315

    Advertising and
     promotion              62,455       48,854      223,800      179,874
    Selling, general and
     administrative      2,138,314    1,527,722    7,038,060    5,864,436
    Research and
     development            81,975       51,939      284,216      208,608
    Total operating
     expenses            2,282,744    1,628,515    7,546,076    6,252,918
    Operating income     1,230,569      402,406    3,183,725      903,397

    Interest income, net
     of expense            (22,816)        (784)     (53,445)     (36,004)
    Foreign currency
     transactions (gain)
     loss                 (893,112)      62,580     (966,736)      70,488
      Pretax income      2,146,497      340,610    4,203,906      868,913

    Income tax benefit    (218,862)    (825,000)    (762,862)    (825,000)
    Net income           2,365,359    1,165,610    4,966,768    1,693,913

    Preferred dividends     25,068       40,643      137,506      161,248

    Net income
     attributable
     to common
     stockholders       $2,340,291   $1,124,967   $4,829,262   $1,532,665

    Net income per
     share- basic            $0.09        $0.04        $0.18        $0.06

    Weighted average
     common shares
     outstanding -
     basic              26,112,376   25,970,280   26,116,499   24,952,440

    Net income per
     share - diluted         $0.08        $0.04        $0.18        $0.06

    Weighted average
     shares outstanding
     - diluted          28,052,370   28,145,652   27,983,263   26,398,565



               Reconciliation of Non-GAAP Financial Information

    Following is a reconciliation of the Non-GAAP financial measure of pretax
income exclusive of currency (gain) loss to the nearest GAAP financial measure
of pretax income for the three months and years ended September 30, 2008 and
2007:


                         For the 3 Months Ended      For the 12 Months Ended
                              September 30,               September 30,
                           2008         2007           2008         2007

    Pretax income
     exclusive of
     currency (gain)
     loss              $1,253,385     $403,190     $3,237,270     $939,401
    Foreign currency
     transactions (gain)
     loss                (893,112)      62,580       (966,736)      70,488
      Pretax income    $2,146,497     $340,610     $4,203,906     $868,913

'/>"/>
SOURCE The Female Health Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference
2. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
5. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
6. Beckman Coulter to Present at Upcoming Healthcare Conferences
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
9. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. BioMarin to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... The Ankle Plating System 3 and ... address fractures of the distal tibia and fibula. This system marks Acumed's continued ... 3 is composed of seven plate families that span the lateral, medial, and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis ... cruciate ligament in her left knee. Lady’s owner Hannah sought the help of Dr ... veterinary surgeon, to repair her cruciate ligament and help with the pain of Lady’s ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... LONDON , May 23, 2016 ... Efficiency by 40% - Frontage Implement a Single Platform ... Quality, Compliance and Traceability Within the Bioanalytical lab Frontage ... the United States and China ... across its laboratory facilities. In addition to serving as the global ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):